Re-Engineering Erythropoietin as an IgG Fusion Protein That Penetrates the Blood−Brain Barrier in the Mouse

Mol. Pharmaceutics, Article ASAP, DOI: 10.1021/mp1001763

 

Qing-Hui Zhou^†, Ruben J. Boado^†‡, Jeff Zhiqiang Lu^‡, Eric Ka-Wai Hui^‡, and William M. Pardridge*^†

Department of Medicine, UCLA, Los Angeles, California 90024, United States, and ArmaGen Technologies, Inc., Santa Monica, California 90401, United States

 

Keywords: drug targeting; drug delivery; Erythropoietin (EPO),  neuroprotective agent,  blood−brain barrier (BBB), chimeric monoclonal antibody (mAb),  transferrin receptor (TfR),  cTfRMAb-EPO, fusion protein,  IgG fusion protein,